Cancer Drugs Approved Based on Surrogate Endpoint: A Retrospective Observational Study in the United States and China
Compared to the United States, RR-supported approvals in China are characterized by higher RR values and a stricter RA pathway. Regulatory authorities in both countries may need to consider both the quantity and quality during cancer drug development based on surrogate endpoints.
Authors
- Jingru Zhong (ORCID: https://orcid.org/0009-0003-2932-5490)
- Yafang Huang (ORCID: https://orcid.org/0000-0003-4396-3870)
- Ting Zhu (ORCID: https://orcid.org/0009-0001-3515-9017)
Institutions
- Capital Medical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/cam4.70864
- Citations
- 1
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 2.63
Funders
- National Natural Science Foundation of China